<DOC>
	<DOCNO>NCT00002505</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's cancer cell may make body build immune response kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness autologous tumor cell vaccination plus immunologic adjuvant treating patient metastatic cancer .</brief_summary>
	<brief_title>Tumor Cell Vaccine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect side effect associate administration autologous tumor cell vaccine together adjuvant interferon gamma sargramostim ( GM-CSF ) patient advanced cancer . II . Determine rate conversion delay tumor hypersensitivity patient receive subcutaneous injection irradiate autologous tumor cell ( autologous vaccine ) . III . Determine effect autologous vaccine vitro assay immune antitumor activity . IV . Determine failure free survival associate use autologous tumor cell line vaccines patient advanced cancer . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , tumor type , disease stage , remission status ( complete vs partial ) , prior therapy , progressive disease ( yes v ) , performance status ( ECOG 0-1 v 2 ) . Patients randomize one two treatment arm . Arm I : Patients receive vaccination irradiate autologous tumor cell subcutaneously ( SQ ) week 1 autologous tumor cell vaccine plus interferon gamma SQ week 2 3 , monthly begin week 8 continue week 24 . Arm II : Patients receive vaccination irradiate autologous tumor cell arm I autologous tumor cell vaccine plus sargramostim ( GM-CSF ) SQ week 2 3 monthly begin week 8 continue week 24 . PROJECTED ACCRUAL : A total 20-30 patient major tumor type ( breast , lung , prostate , colorectal , sarcoma , renal , melanoma ) accrue study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer document regional lymph node distant metastasis consider cured standard therapy Achievement maximum benefit ( i.e. , CR PR ) cytoreductive therapy prior entry allow Eligible tumor type include : Breast Prostate Colorectal Sarcoma Lung Renal cell Melanoma Large resect primary cancer risk recurrence standard adjuvant therapy available Viable autologous tumor cell derive autologous tumor cell line require No active brain metastasis Previously treat responsive brain metastasis allow unless corticosteroid dependent PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hematocrit least 30 % Hepatic : Bilirubin le 2.0 mg/dL PT PTT normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require medication Pulmonary : Respiratory reserve must reasonable No requirement supplemental oxygen No dyspnea rest PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow No concurrent biologic therapy ( include cyclosporine ) Chemotherapy : At least 24 hour since prior cyclophosphamide At least 4 week since systemic antineoplastic chemotherapy recover Endocrine therapy : Homeopathic corticosteroid allow At least 4 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : Prior radiotherapy allow Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>